Connect to share and comment

Novartis says lung cancer patients respond to drug in study

ZURICH (Reuters) - Novartis said late on Wednesday that a majority of patients given a development drug against non-small cell lung cancer had responded to the treatment, according to study results published in the New England Journal of Medicine. The Basel-based drugmaker's LDK378 has been declared a "breakthrough therapy", a designation created by the U.S. Food and Drug Administration in 2012 to help speed drugs to market that treat serious or life-threatening conditions and are deemed likely to work better than existing treatments.

GSK disappointed with lung cancer treatment results, continues trial

LONDON (Reuters) - British pharmaceutical company GlaxoSmithKline said it was disappointed by some of the results of a stage III trial for a lung cancer treatment but would continue with it as there could still be a group of patients who may benefit. GSK said on Thursday that its MAGE-A3 antigen-specific cancer immunotherapeutic did not meet two of its targets in a phase III non-small cell lung cancer (NSCLC) clinical trial but continued to assess it with regards to a third target.

Pfizer says lung cancer drug fails two late-stage studies

(Reuters) - Pfizer Inc said its experimental lung cancer drug failed to meet its goals in two late-stage studies in patients with advanced non-small cell lung cancer. The company said the drug, dacomitinib, did not show improved survival without the cancer worsening in patients when compared with another non-small cell lung cancer drug. The patients were previously treated with chemotherapy. Pfizer said the drug did not prolong overall survival compared with a placebo in a second study.

Pfizer says lung cancer drug fails two late-stage studies

(Reuters) - Pfizer Inc said its experimental lung cancer drug failed to meet its goals in two late-stage studies in patients who received prior treatment for advanced non-small cell lung cancer. The company said patients given the drug, dacomitinib, did not show improved survival without the cancer worsening, compared with another non-small cell lung cancer drug. The patients in this trial, dubbed Archer 1009, were previously treated with chemotherapy.

Blood test may help spot early lung cancers

An experimental blood test has shown promise toward detecting early lung cancer and may offer a more accurate tool than scans and invasive biopsies, researchers said Wednesday. Only about one in five patients who undergo surgery or a biopsy for a small lung mass found during a computerized tomography (CT) scan actually have cancer, and experts say there is a great need for better technology. Lung cancer is the world's most common and deadliest cancer, killing about 1.3 million people each year according to the World Health Organization. Smoking is the primary cause.

'App' helps predict if lung lesions seen on CT are cancerous or benign: study

TORONTO - Canadian researchers have developed a software app that they hope will improve lung cancer screening around the world. The risk-calculating software can predict with a high level of accuracy whether lesions, or nodules, in the lungs detected on a CT scan are likely to be malignant or benign. That can help doctors determine whether a patient at high risk for lung cancer is likely to need an invasive biopsy or surgery, said co-principal investigator Dr. Stephen Lam, chair of the Provincial Lung Tumour Group at the B.C. Cancer Agency.

Risk calculator boosts odds of finding lung cancer

A new software tool may help doctors eliminate mistakes when judging whether a spot that turns up on a smoker's lung scan is cancerous or not, researchers said Wednesday. The clinical risk assessment method described in the New England Journal of Medicine helped correctly decide nine times out of 10 whether a spot or lesion was benign or malignant. Computed tomography (CT) scans can save lives, but they are imperfect and can also lead to unnecessary surgery as much as 25 percent of the time, research has shown.

FDA approves Boehringer drug to treat advanced lung cancer

(Reuters) - The U.S. Food and Drug Administration approved a lung cancer drug made by Boehringer Ingelheim to treat patients who are suffering from late stage non-small cell lung cancer and whose tumors express a specific type of gene mutation. The drug, Gilotrif, was approved along with a companion diagnostic kit that can help determine if a patient's lung cancer cells express the epidermal growth factor receptor (EGFR) gene mutation.

Many cancer patients expect palliative care to cure

By Kathryn Doyle NEW YORK (Reuters Health) - In a survey of patients with terminal lung cancer, nearly two-thirds did not understand that radiation treatments intended only to ease their symptoms would not cure their disease. Among the nationwide sample of patients with advanced lung cancers, four out of five thought the radiation would help them live longer and two in five believed it might cure their cancers.

Synta drug shown to extend lives of certain lung cancer patients

CHICAGO (Reuters) - A drug designed to block a protein known to help cancer cells grow was shown in a mid-stage trial to lengthen survival in patients with advanced lung cancer that worsened after initial treatment, researchers said on Monday. The results, presented at a meeting of the American Society of Clinical Oncology in Chicago, are the first time an agent in a class known as heat shock protein 90 inhibitors, HSP90 for short, has been shown to be safe and effective, they said.
Syndicate content